NCT06169241 Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients
| NCT ID | NCT06169241 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | National Institute of Cardiology, Laranjeiras, Brazil |
| Condition | Arterial Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 50 participants in total. It began in 2023-11-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.
Eligibility Criteria
Inclusion Criteria: * Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days. Exclusion Criteria: * neoplasms * heart failure * use of medications with nitrate in their formula * patients undergoing renal denervation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06169241 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06169241 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06169241 currently recruiting?
Yes, NCT06169241 is actively recruiting participants. Contact the research team at etibi@uol.com.br for enrollment information.
Where is the NCT06169241 trial being conducted?
This trial is being conducted at Rio de Janeiro, Brazil.
Who is sponsoring the NCT06169241 clinical trial?
NCT06169241 is sponsored by National Institute of Cardiology, Laranjeiras, Brazil. The trial plans to enroll 50 participants.